Aquestive Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AQST and other ETFs, options, and stocks.

About AQST

Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. Its product pipeline include Libervant, AQST-108, AQST-305, Suboxone and Zuplenz. 

CEO
Daniel Barber
CEODaniel Barber
Employees
142
Employees142
Headquarters
Warren, New Jersey
HeadquartersWarren, New Jersey
Founded
2004
Founded2004
Employees
142
Employees142

AQST Key Statistics

Market cap
605.47M
Market cap605.47M
Price-Earnings ratio
-7.86
Price-Earnings ratio-7.86
Dividend yield
Dividend yield
Average volume
3.05M
Average volume3.05M
High today
$5.60
High today$5.60
Low today
$4.94
Low today$4.94
Open price
$5.49
Open price$5.49
Volume
3.31M
Volume3.31M
52 Week high
$5.80
52 Week high$5.80
52 Week low
$2.12
52 Week low$2.12

AQST News

TipRanks 8h
Aquestive Therapeutics Highlights at Global Investor Conference

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to...

TipRanks 9h
Aquestive Therapeutics price target raised to $8 from $7 at Oppenheimer

Oppenheimer raised the firm’s price target on Aquestive Therapeutics (AQST) to $8 from $7 and keeps an Outperform rating on the shares. The firm notes that last...

Simply Wall St 3d
Aquestive Therapeutics, Inc. Stocks Shoot Up 28% But Its P/S Still Looks Reasonable

Aquestive Therapeutics, Inc. ( ) shares have continued their recent momentum with a 28% gain in the last month alone. Taking a wider view, although not as stron...

Aquestive Therapeutics, Inc. Stocks Shoot Up 28% But Its P/S Still Looks Reasonable

Analyst ratings

100%

of 10 ratings
Buy
100%
Hold
0%
Sell
0%

More AQST News

Benzinga 4d
FDA Confirms Direct Review Path For Aquestive's Allergy Treatment

The U.S. Food and Drug Administration (FDA) on Thursday informed Aquestive Therapeutics, Inc. AQST that an advisory committee meeting is not required for Anaphy...

FDA Confirms Direct Review Path For Aquestive's Allergy Treatment
TipRanks 5d
Optimistic Buy Rating for Aquestive Therapeutics Driven by Anaphylm’s Market Potential and Strategic Leadership

Aquestive Therapeutics (AQST) has received a new Buy rating, initiated by LifeSci Capital analyst, . Elevate Your Investing Strategy: Take advantage of TipRanks...

People also own

Based on the portfolios of people who own AQST. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.